Please login to the form below

lifitegrast

This page shows the latest lifitegrast news and features for those working in and with pharma, biotech and healthcare.

Novartis to sell eye-care products to Bausch + Lomb in deal worth up to $2.5bn

The transaction includes the Swiss drugmaker’s non-steroid, anti-inflammatory eye drop Xiidra (lifitegrast ophthalmic solution), which is specifically approved to treat the signs and symptoms of dry eye disease

Latest news

Shire files dry eye drug lifitegrast in Europe

Analysts predict Xiidra could become a $1bn product. Shire is awaiting the go-ahead of lifitegrast in the EU, seeking approval for the would-be dry eye disease blockbuster. ... Once fully rolled out, analysts have suggested lifitegrast could become a
Shire licences Parion dry eye drug in $535m deal

All told the deal could be worth up to $535m for North Carolina biotech Parion, while Shire adds to the pipeline behind its recently-approved dry eye disease therapy Xiidra (lifitegrast).
Shire launches dry eye drug Xiidra in US

The Anglo-Irish company is making much of that fact that Xiidra (lifitegrast) - the first in a new class of lymphocyte function-associated antigen 1 (LFA-1) antagonist - is the only
FDA finally approves Shire’s potential blockbuster Xiidra

The only prescription eye drop indicated for the treatment of both signs and symptoms of this condition, Xiidra (lifitegrast ophthalmic solution) is taken twice a day. ... says. Lifitegrast, which was licensed from SARcode Bioscience in 2013, is a
FDA deals a big blow to Shire's late-stage pipeline

Additional data required before firm can apply for re-approval. Shire suffered a major setback last week when the FDA declined to approve its lifitegrast treatment for dry eye disease, which ... Lifitegrast is a small molecule integrin beta(2) antagonist

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Pharma deals during March 2013

Shire's second acquisition of the month was also in the field of ophthalmology bringing SARcode Bioscience for $160m plus additional milestones with its phase III stage product Lifitegrast for dry ... Lifitegrast is a small-molecule integrin antagonist